Qiang Li

Dr. Qiang Li


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
YZYanzhao Zhou
Yanzhao Zhou
KYKun Yuan
Kun Yuan
YYYi Yang
Yi Yang
ZJZemin Ji
Zemin Ji
DZDezheng Zhou
Dezheng Zhou
ZJZhou Jinxue
Zhou Jinxue
Surgery remains the preferred treatment option for early-stage gallbladder cancer (GBC). According to the anatomical position of the primary tumor, accurate preoperative stage and strict control of surgical indications, appropriate surgical strategies are selected to achieve the optimal surgical effect. However, most patients have already been at the locally advanced stage or the tumor has metastasized at the initial diagnosis. The postoperative recurrence rate and 5-year survival rate remain unsatisfactory even after radical resection for gallbladder cancer. Hence, there is an urgent need for more treatment options, such as neoadjuvant therapy, postoperative adjuvant therapy and first-line and second-line treatments of local progression and metastasis, in the whole-course treatment management of gallbladder cancer patients. In recent years, the application of molecular targeted drugs and immunotherapy has brought greater hope and broader prospects for the treatment of gallbladder cancer, but their effects in improving the prognosis of patients still lack sufficient evidence-based medicine evidence, so many problems should be addressed by further research. Based on the latest progress in gallbladder cancer research, this review systematically analyzes the treatment trends of gallbladder cancer.

14 July 2021 in Cancer Biology & Medicine
Verified
Journal Article
Open access
PDF file
YTYe Tian
Ye Tian
QLQiang Li
Qiang Li
YPYuan Pan
Yuan Pan
Prospective study of the effect of ERAS on postoperative recovery and complications in patients with gastric cancer

1 June 2024 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
YZYanzhao Zhou
Yanzhao Zhou
JOJingzhong Ouyang
Jingzhong Ouyang
HYHongcai Yang
Hongcai Yang
ZWZhengzheng Wang
Zhengzheng Wang
YYYi Yang
Yi Yang
QLQiang Li
Qiang Li
Purpose: The impact of visceral adiposity on overall survival (OS) in hepatocellular carcinoma (HCC) receiving immunotherapy was unclear. We aimed to determine how visceral adiposity affected OS and explore the interrelationships between visceral adiposity, body mass index (BMI), and other body compositions. Patients and Methods: Data from three centers were retrospectively analyzed. Skeletal muscle index (SMI), skeletal muscle density (SMD), visceral adipose tissue index (VATI), and subcutaneous adipose tissue index (SATI) were used to define each body composition. The BMI subgroups included the underweight, the normal weight, and the obesity. The Log rank test compared survival curves calculated by the Kaplan-Meier method. The relationships between body compositions and BMI with OS were examined using Cox proportional risk regression models. Results: A total of 305 patients who met the criteria were included. Patients with low VATI had significantly worse OS (P = 0.001). The protections of VATI (P = 0.011) on OS were independent of covariates. However, after additional adjustment of SMI, the effect of VATI on OS disappeared (P = 0.146), but the effect of SMD on OS did not (P = 0.021). BMI has a significant U-shaped relationship with OS, and the effect of BMI on OS equally disappeared after additional adjustment by SMI. Conclusion: This study first demonstrated that high VATI and mid-level BMI were protective for the survival of patients with HCC receiving immunotherapy. Skeletal muscle status (including SMI and SMD) may be the better predictor for outcomes of patients with HCC receiving immunotherapy.

11 May 2023 in Academic Radiology
Verified
Journal Article
Closed access
YZYanzhao Zhou
Yanzhao Zhou
KYKun Yuan
Kun Yuan
YYYi Yang
Yi Yang
XSXiao Shan
Xiao Shan
ZJZemin Ji
Zemin Ji
QLQiang Li
Qiang Li